AKBA Q2 2022 Earnings — Akebia Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AKBAAkebia Therapeutics, Inc.

$365M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$126M+138.8% YoY

Gross Profit

$108M85.3% margin

Operating Income

$34M27.0% margin

Net Income

$29M23.3% margin

EPS (Diluted)

$0.15

QoQ Revenue Growth

+104.8%

Cash Flow

Operating Cash Flow

-$31M

Free Cash Flow

-$31M

Stock-Based Comp.

$7M

Balance Sheet

Total Assets

$522M

Total Liabilities

$460M

Stockholders' Equity

$62M

Cash & Equivalents

$144M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$126M	$53M	+138.8%
Gross Profit	$108M	$418,000	+25681.1%
Operating Income	$34M	-$79M	+142.9%
Net Income	$29M	-$83M	+135.5%

Revenue Segments

License Collaboration And Other Revenue

$83M66%

Product

$44M34%